cancerous tumor News
-
Investment attraction IR Bilirubin nano platform technology-based treatment Bilix
This is the IR video of Vilix Co., Ltd., the 4th KBIC Star Day of the Health Industry Innovation and Startup Center. Introducing the treatment based on bilirubin nano-platform technology. “Bilix Co., Ltd.” succeeded in chemical synthesis of bilirubin for the first time in the world The nanoparticle itself: BRIXELLE-INFLA anti-inflammatory drug Nanoparticles + Hydrophobic ...
-
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 18, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the ...
-
JCRI-ABTS and USMI Successfully Complete Phase 1 Multi-Center Clinical Trial Using Canady Helios™ Cold Plasma for the Treatment of Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195). The medical centers involved in the study were Rush ...
-
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge ...
-
USMI Developing the First Surgical Robot for Cancer Surgery
US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery. The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures. Features of the new Canady Surgical ...
-
Icecure Medical announces updated regulatory strategy in china for the icesense3 system to treat Cancerous Tumors with Cryoablation
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3® system, which was granted ...
-
Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting
Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the SITC Annual Meeting in National Harbor, Maryland on November 9, 2019. The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to ...
-
Curasight expands its strategy and strengthen its position as a theranostic company
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. With reference to the ...
By Curasight
-
Surgeon Explains How MarginProbe® Protects Cosmetic Outcomes While Preventing Re-excision in Breast Conserving Surgery
Dr. Kerry-Ann McDonald, a breast surgeon at Boca Raton Regional Hospital in Boca Raton, Florida, credits her interest in medicine to her early days as a hospital volunteer. After entering the medical field and beginning residency, her path to becoming a surgeon was clear. “I always knew I wanted to be a surgeon because of the satisfaction that comes with helping others, and the immediate ...
-
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. CTT1403 is a peptidomimetic drug that targets Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate ...
-
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that the U.S. Patent and ...
-
Icecure Medical announces new independent data published in the journal of cancer therapy showing that percutaneous Cryoablation presents a potential substitute for lumpectomy for tumors <15mm using Prosense
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in ...
-
JCRI Discovers the Mechanism using Canady Helios Cold Plasma to Induce Cell Death in Breast Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article ...
-
Pioneering VeraForm® in Head and Neck Cancer Treatment: Sarcomatoid Carcinoma Tumor Bed Marking
Head and neck cancer surgery presents a number of unique challenges, not only for the surgeon but for the radiation oncologist who will subsequently treat those patients. Great care with an emphasis on precision must be taken to ensure that critical structures and tissues avoid collateral damage when possible. However, given the surgical site often lies in soft tissue, exact identification of the ...
-
Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. Dako developed the ...
-
Icecure Medical announces first peer reviewed publication for the 3-year interim analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor ...
-
Matthew Gdovin, Ph.D. to Present at the 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology Satellite Session
Matthew Gdovin, Ph.D., University of Texas – San Antonio Professor and Chief Science Officer of Vitanova Biomedical, the San Antonio, Texas-based biotech company dedicated to delivering transformative cancer therapy utilizing their patented Light-Activated Intracellular Acidosis (LAIA) platform technology, will present at the 2nd International Prostate Cancer Symposium and Inaugural World ...
-
Cannabis Sequencing and New Cancer Research
In 2014, the entire genome of Cannabis stavia L. was sequenced. This news received national attention with eye-catching headlines such as: “Marijuana Genome Sequenced for Health, Not Highs”. Researchers and oncologists took note, not due to the attention-grabbing headlines, but because their focus was to pair the decoded cannabis genome research with sequencing of the ...
-
Berkeley Lab news release: Berkeley scientists find new way to get physical in the fight against cancer
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals. Now, a new road for future therapies may have been opened with scientific evidence for a ...
-
ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you